Disease · MONDO_0019437
enthesitis-related juvenile idiopathic arthritis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. enthesitis-related juvenile idiopathic arthritis. Diseases, record MONDO_0019437. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019437
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs6
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ADALIMUMAB | CHEMBL1201580 | Antibody | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ETANERCEPT | CHEMBL1201572 | Protein | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| BARICITINIB | CHEMBL2105759 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BIMEKIZUMAB | CHEMBL4297700 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IXEKIZUMAB | CHEMBL1743034 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TOFACITINIB | CHEMBL221959 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets7
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| IL17A | Interleukin-17A | 2 | Interleukin 17A inhibitor | Phase 3 | https://conductscience.org/library/genes/3605 | Drugs and targets |
| JAK1 | Janus Kinase (JAK) | 2 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor | Phase 3 | https://conductscience.org/library/genes/3716 | Drugs and targets |
| JAK2 | Janus Kinase (JAK) | 2 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor | Phase 3 | https://conductscience.org/library/genes/3717 | Drugs and targets |
| TNF | Tumor necrosis factor | 2 | TNF-alpha inhibitor | Phase 3 | https://conductscience.org/library/genes/7124 | Drugs and targets |
| IL17F | Interleukin-17F | 1 | Interleukin-17F inhibitor | Phase 3 | https://conductscience.org/library/genes/112744 | Drugs and targets |
| JAK3 | Janus Kinase (JAK) | 1 | Janus Kinase (JAK) inhibitor | Phase 3 | https://conductscience.org/library/genes/3718 | Drugs and targets |
| TYK2 | Janus Kinase (JAK) | 1 | Janus Kinase (JAK) inhibitor | Phase 3 | https://conductscience.org/library/genes/7297 | Drugs and targets |
Trials7
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02592434 | Efficacy Study Of Tofacitinib In Pediatric JIA Population | Phase 3 | 225 | 2020-02-21 | Juvenile Idiopathic Arthritis | TOFACITINIB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03773978 | A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis | Phase 3 | 220 | 2022-10-07 | Juvenile Idiopathic Arthritis | BARICITINIB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00962741 | Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis | Phase 3 | 127 | 2012-07-19 | Arthritis, Juvenile Idiopathic | ETANERCEPT | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01421069 | Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis | Phase 3 | 109 | 2022-11-14 | Juvenile Idiopahtic Arthritis | ETANERCEPT | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT04527380 | A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis | Phase 3 | 101 | 2025-06-05 | Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis | ADALIMUMAB, IXEKIZUMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01166282 | A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis | Phase 3 | 46 | 2016-06-21 | Enthesitis Related Arthritis (ERA) | ADALIMUMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT06668181 | An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis | Phase 3 | 40 | Enthesitis-related Arthritis, Juvenile Psoriatic Arthritis | BIMEKIZUMAB | Open Targets' reading of its record | ClinicalTrials.gov |
Comparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ixekizumab - OLT Period vs Adalimumab - OLT Period: deaths from any cause | 0 of 81 | 0 of 20 | 101 | NCT04527380 | Trial comparisons |
| Ixekizumab - OLT Period vs Adalimumab - OLT Period: serious adverse events | 3 of 81 | 3 of 20 | 101 | NCT04527380 | Trial comparisons |
Papers from its trials11
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 26223543 | RESULT | 1 | PubMed |
| 42011511 | DERIVED | 2 | PubMed |
| 41785908 | DERIVED | 1 | PubMed |
| 40915298 | DERIVED | 1 | PubMed |
| 40312101 | DERIVED | 1 | PubMed |
| 38298058 | DERIVED | 1 | PubMed |
| 37423231 | DERIVED | 1 | PubMed |
| 37140539 | DERIVED | 2 | PubMed |
| 34767764 | DERIVED | 1 | PubMed |
| 31122296 | DERIVED | 2 | PubMed |
1 to 10 of 11
See all 11 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019437
GET https://conductscience.org/api/diseases/v1/MONDO_0019437/drugs